Vectormune FP ILT + AE
fowlpox, avian infectious laryngotracheitis vaccine (live, recombinant) and avian encephalomyelitis vaccine (live)
Table of contents
Overview
Vectormune FP ILT + AE is a veterinary vaccine used in chickens to reduce skin damage due to fowlpox (FP), to reduce the clinical signs and tracheal (windpipe) damage due to avian infectious laryngotracheitis (ILT) and to prevent loss of egg production due to avian encephalomyelitis (AE).
Vectormune FP ILT + AE contains the active substances live fowlpox virus which has been modified to produce certain proteins found in avian infectious laryngotracheitis virus and a specific strain of avian encephalomyelitis virus.
Authorisation details
Product details | |
---|---|
Name |
Vectormune FP ILT + AE
|
Agency product number |
EMEA/V/C/005077
|
Active substance |
live recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus (rFP-LT) and avian encephalomyelitis virus, strain Calnek 1143 (AE)
|
International non-proprietary name (INN) or common name |
fowlpox, avian infectious laryngotracheitis vaccine (live, recombinant) and avian encephalomyelitis vaccine (live)
|
Species |
Chicken
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
Not assigned
|
Publication details | |
---|---|
Marketing-authorisation holder |
CEVA-Phylaxia Co. Ltd.
|
Revision |
1
|
Date of issue of marketing authorisation valid throughout the European Union |
24/04/2020
|
Contact address |
Product information
29/06/2020 Vectormune FP ILT + AE - EMEA/V/C/005077 - IAIN/0001
Contents
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pharmacotherapeutic group
-
Immunologicals for aves
-
Live viral vaccines
-
Domestic fowl
Therapeutic indication
For active immunisation of chickens of 8 to 13 weeks of age in order to reduce the skin lesions due to fowlpox, to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis and to prevent egg production losses due to avian encephalomyelitis.